- Home
- KYN vs HRMY Comparison
KYN vs HRMY Comparison
Compare KYN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYN
- HRMY
- Stock Information
- Founded
- KYN 2004
- HRMY 2017
- Country
- KYN United States
- HRMY United States
- Employees
- KYN N/A
- HRMY N/A
- Industry
- KYN Finance/Investors Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- KYN Finance
- HRMY Health Care
- Exchange
- KYN Nasdaq
- HRMY Nasdaq
- Market Cap
- KYN 2.0B
- HRMY 1.8B
- IPO Year
- KYN N/A
- HRMY 2020
- Fundamental
- Price
- KYN $12.44
- HRMY $34.00
- Analyst Decision
- KYN
- HRMY Strong Buy
- Analyst Count
- KYN 0
- HRMY 9
- Target Price
- KYN N/A
- HRMY $54.44
- AVG Volume (30 Days)
- KYN 561.5K
- HRMY 642.5K
- Earning Date
- KYN 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- KYN 8.99%
- HRMY N/A
- EPS Growth
- KYN N/A
- HRMY 13.13
- EPS
- KYN 0.71
- HRMY 2.62
- Revenue
- KYN N/A
- HRMY $744,852,000.00
- Revenue This Year
- KYN N/A
- HRMY $20.10
- Revenue Next Year
- KYN N/A
- HRMY $18.01
- P/E Ratio
- KYN $13.79
- HRMY $13.10
- Revenue Growth
- KYN N/A
- HRMY 20.62
- 52 Week Low
- KYN $7.84
- HRMY $26.47
- 52 Week High
- KYN $9.88
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- KYN 51.39
- HRMY 58.91
- Support Level
- KYN $12.28
- HRMY $31.70
- Resistance Level
- KYN $12.50
- HRMY $35.08
- Average True Range (ATR)
- KYN 0.19
- HRMY 0.95
- MACD
- KYN -0.02
- HRMY 0.27
- Stochastic Oscillator
- KYN 41.94
- HRMY 71.80
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.